Devyser has been awarded a tender for Devyser RHD, its product for non-invasive fetal RHD status in maternal plasma during pregnancy. The tender with Wales Blood Services covers fetal RHD testing in Wales and is valid for a period of three years, with the potential of a two-year extension. Indicative order value is estimated to amount to SEK 1 million annually.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
94 SEK | -6.00% | -7.84% | +19.59% |
Apr. 25 | Devyser Receives IVDR Approval for Post-Transplant Monitoring Software | CI |
Apr. 23 | Devyser Diagnostics AB Enters into Co-Marketing Agreement with Hamilton Bonaduz AG | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.59% | 151M | |
+21.89% | 47.9B | |
+46.56% | 41.42B | |
-2.38% | 40.7B | |
-6.20% | 28.92B | |
+10.97% | 25.55B | |
-21.56% | 19.27B | |
-1.56% | 12.15B | |
+30.62% | 12.14B | |
-0.57% | 11.99B |
- Stock Market
- Equities
- DVYSR Stock
- News Devyser Diagnostics AB
- Devyser wins tender for non-invasive fetal RHD testing in Wales